Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
We are conducting a prospective single-arm clinical trial on Y-90-glass radioembolization to determine (primary objective) if patient-specific voxel-dosimetry based treatment plan of target mean absorbed dose ≥200 Gy to tumor will yield an objective response rate (ORR) greater than 75% in patients with hepatocellular carcinoma at 6 month follow up.
Background: Currently, there are limited therapeutic options for patients with advanced midgut neuroendocrine tumors progressing on first-line somatostatin analog therapy. Methods: NETTER-1 is the first phase III, randomized trial evaluating 177Lu-DOTA0-Tyr3-Octreotate (Lutathera®) in patients with progressive, somatostatin receptor positive midgut NETs. 230 patients were randomized to receive Lutathera 7.4 GBq every 8 weeks (x4 administrations) versus Octreotide LAR 60 mg every 4 weeks.
O-009NETTER-1 phase III: efficacy and safety results in patients with midgut neuroendocrine tumors treated with 177Lu-dotatate J. Strosberg1, E. Wolin2, B. Chasen3, M. Kulke4, D. Bushnell5, M. Chaplin6, R. Baum7, P. Kunz8, T. Hobday9, K. Oberg10, M. Lopera Sierra11, D. Kwekkeboom12, P. Ruszniewski13, E. Krenning14 and A. Hendifar15 1H.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
